OptiBiotix Health PLC (AIM:OPTI) (OptiBiotix Health PLC (AIM:OPTI)) Stephen O'Hara presents the findings of their third human volunteer study on its cholesterol reducing probiotic, LPLDL.
Previous studies have shown that LPLDL was safe and that the higher the starting level of cholesterol, the greater the cholesterol reduction. The aim of the third study was to provide further data in a different population group of adults with hypercholesterolaemia (TC³6mM).
He says hypercholesterolaemic adults are most likely to benefit from a cholesterol reducing effect and the target population of greatest commercial interest group to commercial partners exploring the potential of LPLDLas an over the counter (OTC) natural consumer health product or drug bio-therapeutic.